Chloroquine
- Generic Name
- Chloroquine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3
- CAS Number
- 54-05-7
- Unique Ingredient Identifier
- 886U3H6UFF
- Background
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Chloroquine was granted FDA Approval on 31 October 1949.
- Indication
Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.
- Associated Conditions
- Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 380
- Registration Number
- NCT01378286
- Locations
- 🇧🇷
Administrative office, Sao Paulo, Brazil
Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
- Conditions
- Malaria, Vivax
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 851
- Registration Number
- NCT01376167
- Locations
- 🇹🇭
GSK Investigational Site, Tak, Thailand
Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01366235
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults
- Conditions
- MalariaPlasmodium Vivax
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Target Recruit Count
- 70
- Registration Number
- NCT01290601
- Locations
- 🇹🇭
Bangkok Hospital for Tropical Diseases/Mahidol University, Bangkok, Thailand
Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- Biological: ImmunizationBiological: Plasmodium falciparum Bloodstage challengeBiological: Plasmodium falciparum mosquito challenge
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT01236612
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- Biological: ImmunizationBiological: Plasmodium falciparum challenge
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01218893
- Locations
- 🇳🇱
Leiden University Medical Centre, Leiden, Netherlands
G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 192
- Registration Number
- NCT01205178
- Locations
- 🇹🇭
GSK Investigational Site, Tak, Thailand
Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 593
- Registration Number
- NCT01178021
- Locations
- 🇦🇫
Provincial Malaria Control Centers (MRC), Kunduz, Afghanistan
Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)
- Conditions
- Plasmodium Vivax Malaria
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 16
- Registration Number
- NCT01107145
- Locations
- 🇧🇷
Hospital Geral Maternidade de Cruzeiro do Sul, Cruzeiro do Sul, Acre, Brazil
🇧🇷Centro de Pesquisa em Patologias Tropicais, Porto Velho, Rondonia, Brazil
🇧🇷Hospital Municipal Teonila Alves, Anajas, Para, Brazil
A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
- Conditions
- Malaria Prophylaxis
- Interventions
- Drug: test chloroquine (CQ) formulation
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT01100060
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.